Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container comprising at least one selenium compound in the form of Se (IV), which is preferably selected from the group consisting of sodium selenite, selenous acid and selenium dioxide, characterized in that the solution comprises dissolved oxygen (DO), preferably 0.5 ppm to 8 ppm DO.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container comprising at least one selenium compound in the form of Se (IV), which is preferably selected from the group consisting of sodium selenite, selenous acid and selenium dioxide, characterized in that the solution comprises dissolved oxygen (DO), preferably 0.5 ppm to 8 ppm DO.

Disclosed are a polysaccharide-peptide composite and a method of preparing the same. The polysaccharide-peptide composite is prepared from a bitter melon peptide (BMP) powder, gardenia fruit oil, a soybean polypeptide powder, an oat dietary fiber powder, a konjac powder, a corn silk, a mulberry leaf extract, a Poria cocos extract, a hawthorn extract, nutritional yeast and a pancreatin. The BMP powder is prepared by temperature-controlled hydrolysis, staged enzymatic hydrolysis and multiple filtrations. The gardenia fruit oil is prepared by staged enzymatic hydrolysis, multi-step centrifugation, filtration and stratification.

Disclosed are a polysaccharide-peptide composite and a method of preparing the same. The polysaccharide-peptide composite is prepared from a bitter melon peptide (BMP) powder, gardenia fruit oil, a soybean polypeptide powder, an oat dietary fiber powder, a konjac powder, a corn silk, a mulberry leaf extract, a Poria cocos extract, a hawthorn extract, nutritional yeast and a pancreatin. The BMP powder is prepared by temperature-controlled hydrolysis, staged enzymatic hydrolysis and multiple filtrations. The gardenia fruit oil is prepared by staged enzymatic hydrolysis, multi-step centrifugation, filtration and stratification.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

A nutritional supplement containing fish oil and selenium has been identified that reduces angiogenesis and/or stem cell content of tumors. A formulation for such a supplement that is both well tolerated and palatable is also provided.